Related Experiment Videos
Variceal bleeding and portal hypertension: still a therapeutic challenge?
1Dept. of Interdisciplinary Endoscopy, University Hospital, Eppendorf, Hamburg, Germany.
Insights
Beta-blockers remain first-line for preventing variceal hemorrhage. Endoscopic variceal ligation (EVL) is preferred over sclerotherapy, but recurrence rates are high, prompting combination therapy research.
Area of Science:
- Gastroenterology
- Hepatology
- Interventional Endoscopy
Background:
- Beta-blockers are standard for primary prevention of variceal hemorrhage.
- Newer agents like carvedilol show promise in reducing hepatic venous pressure gradient.
- Endoscopic therapies have evolved significantly for managing bleeding varices.
Purpose of the Study:
- To review current strategies for preventing and treating variceal hemorrhage.
- To compare the efficacy of different beta-blockers and endoscopic techniques.
- To assess the role of newer modalities like endosonography and TIPS.
Main Methods:
- Review of current literature on variceal hemorrhage management.
- Comparison of pharmacological treatments (beta-blockers, nitrates) and endoscopic interventions (EVL, EVS, cyanoacrylate).
- Evaluation of diagnostic tools like endosonography (EUS) and interventional procedures like transjugular intrahepatic portosystemic shunt (TIPS).
Main Results:
- Nonselective beta-blockers with anti-alpha1 activity may be superior to propranolol.
- Endoscopic variceal ligation (EVL) is favored over endoscopic variceal sclerotherapy (EVS) due to lower morbidity, though recurrence rates are a concern.
- Combination therapy (EVL + EVS) and cyanoacrylate injection for fundic varices show improved outcomes.
- Endosonography (EUS) aids in assessing eradication and guiding therapy.
- Transjugular intrahepatic portosystemic shunt (TIPS) is not superior to endoscopic treatment for secondary prevention.
Conclusions:
- Beta-blockers and EVL are key treatments for variceal hemorrhage.
- Optimizing endoscopic techniques and combination therapies is crucial for reducing recurrence.
- EUS and cyanoacrylate injection represent advancements in managing complex cases.
Abstract:
In the primary prevention of variceal hemorrhage, beta-blockers continue to be the first-line treatment. Newer nonselective beta-blockers with anti-alpha1-adrenergic activity, such as carvedilol, appear to have a better impact on reducing the hepatic venous pressure gradient than propranolol. The addition of isosorbide mononitrate appears to improve the effectiveness of beta-blockers in primary prophylaxis, but not that of somatostatin in the treatment of acute variceal hemorrhage. The use of vasoactive drugs alone in acute variceal bleeding has not proved to be more effective than endoscopic treatment. The advent of endoscopic variceal ligation (EVL) has strengthened the role of endoscopy in the management of bleeding esophageal varices. EVL has improved the results, particularly in terms of lowering the treatment-related morbidity, compared with endoscopic variceal sclerotherapy (EVS). However, the variceal recurrence rate after initial eradication with EVL is relatively high. In contrast to synchronous combined therapy with EVL plus EVS, metachronous combination of EVL and low-dose EVS may improve the results of EVL alone. For bleeding fundic varices, obliteration using cyanoacrylate is currently the treatment of choice. Endosonography (EUS) is coming into more widespread use in the assessment of variceal eradication and in further attempts to improve the results of endoscopic injection therapy. According to two meta-analysis studies, transjugular intrahepatic portosystemic shunt (TIPS) is not yet capable of replacing endoscopic treatment in the secondary prevention of variceal bleeding.